A focused biopharmaceutical company · 7/2/2020 · A focused biopharmaceutical company General...
Transcript of A focused biopharmaceutical company · 7/2/2020 · A focused biopharmaceutical company General...
A focused biopharmaceutical company
General presentation for investors and analysts June 2020
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’theGroup’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share orother financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, bytheir very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially differentfrom those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and theGroup undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materiallyfrom those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure ordelay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development orapproval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact ofcompetitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic,regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the qualityor execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in theGroup’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; therisk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain adiverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketedmedicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasinglystringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure infinancial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that the COVID-19 globalpandemic may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financialresults or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
2
Forward-looking statements disclaimer
3
Strategic priorities
The newstrategicpriorities
Deliver growth and therapy area leadership
Accelerate innovative science
Be a great place to work
Scientific collaborations are key drivers behind the move
4
Cambridge, UK: the global R&D headquarter
Three therapy areas
5
Focused strategy
Respiratory & Immunology
Cardiovascular,Renal & MetabolismOncology
Commitment to further focus the portfolio
Positive pipeline progression supports sustainable growth
6
2019: another year of very significant news flow
1. Type-1 diabetes 2. Respiratory syncytial virus 3. Hypereosinophilic syndrome 4. Eosinophilic oesophagitis 5. Idiopathic pulmonary fibrosis 6. Complete response letter.Indications used above are not complete indications as per medicine label. Analysis based on stock-exchange announcements published on astrazeneca.com.
ForxigaT1D1
approval (EU)
ForxigaT1D
approval (JP)
Qternmet XRT2D
approval (US)
Lynparzabreast cancerapproval (EU)
LynparzaOC 1L (SOLO-1)approval (EU)
BreztriCOPD
approval (JP)
BevespiCOPD
approval (JP)
LynparzaOC 1L (SOLO-1)
approval (JP)
ForxigaT2D CVOT
approval (EU)
TagrissoNSCLC 1L
approval (CN)
roxadustatanaemia CKDapproval (CN)
Fasenraasthma (pen)approval (US)
QtrilmetT2D
approval (EU)
FarxigaT2D CVOT
approval (US)
CalquenceCLL front lineapproval (US)
CalquenceCLL relapsed/refractory
approval (US)
LynparzaOC 1L (SOLO-1)approval (CN)
Enhertubreast cancer 3L
approval (US)
Imfinziunr. SIII NSCLCapproval (CN)
BreztriCOPD
approval (CN)
Lynparzapanc. cancer 1Lapproval (US)
nirsevimabRSV2
PRIME designation(EU)
nirsevimabRSV
breakthrough designation (US)
FasenraHES3
orphan designation (US)
saracatinibIPF5
orphan designation (US)
Lynparzapancreatic cancer
Phase III pos.
BrilintaCAD/T2D
Phase III pos.
selumetinibNF1
breakthrough designation (US)
CalquenceCLL relapsed/refractory
Phase III pos.
Enhertubreast cancer 3LReg. Phase II pos.
ImfinziSCLC
Phase III pos.
CalquenceCLL front linePhase III pos.
roxadustatanaemia from CKD
Phase III safety
Lynparzaprostate cancer 2L
Phase III pos.
TagrissoNSCLC
Phase III pos. (OS)
LynparzaOC 1L (PAOLA-1)
Phase III pos.
FarxigaHF
Phase III pos.
CalquenceCLL
breakthrough designation (US)
FasenraEoE4
orphan designation (US)
anifrolumablupus (SLE)
Phase III pos.
Imfinzi +/- tremeNSCLC 1L (POSEIDON) (PFS)
Phase III pos.
BreztriCOPD (ETHOS)Phase III pos.
Enhertubreast cancer
Priority Review (US)
ImfinziSCLC
Priority Review (US)
selumetinibNF1
Priority Review (US)
FarxigaT1D
CRL6 (US)
PT010COPD
CRL (US)
Imfinzi + tremeNSCLC 1L (NEPTUNE)
Phase III neg.
21Approvals of new medicines or
life-cycle management indications
24Data, regulatory designations
3Unfavourable outcomes
Solid pipeline moving forward
7
Oncology: ‘what’s next’
What’s next What’s nowPhase I/II new medicines, selected Phase III new medicines
adavosertib(WEE11 inhibitor)
solid tumours
monalizumab(NKG2a5 mAb6)
head & neck, colorectal cancers
capivasertibbreast cancer
ceralasertib(ATR2 inhibitor)
solid tumours, blood cancers
oleclumab(CD737 mAb)
lung, pancreatic cancers
savolitinib13
NSCLCtremelimumabmultiple cancers
AZD9833(SERD3, oral)breast cancer
AZD4635(A2AR8 inhibitor)
solid tumoursPhase III lifecycle management, major
AZD5991(MCL14 inhibitor)
blood cancers
danvatirsen(STAT39inhibitor)
bladder, head & neck, lung cancers
Lynparzamultiple cancers
AZD2811(Aurora B inhibitor)
solid tumours, blood cancers
MEDI5752(PD-110 / CTLA-411)
solid tumours
TagrissoNSCLC
Enhertumultiple cancers
AZD0466(Bcl-212/xL)
blood cancers
Imfinzimultiple cancers
Calquencemultiple cancers
1. Tyrosine kinase WEE1 2. Ataxia telangiectasia and rad3-related kinase 3. Selective oestrogen receptor degrader 4. Induced myeloid leukaemia cell differentiation protein 5. Inhibitory cell surface receptor covalently bound to CD94 6. Monoclonal antibody 7. 5'-nucleotidase 8. Adenosine A2A receptor 9. Signal transducer and activator of transcription 3 10. Programmed cell death protein 1 11. cytotoxic T-lymphocyte-associated protein 4 12. B-cell lymphoma 2 13. Potentially pivotal Phase II.
Phase III decision
Highpriority
Expanding pipeline, including immunology
8
BioPharmaceuticals: ‘what’s next’
What’s next What’s nowPhase I/II new medicines, selected Phase III new medicines
cotadutide(GLP-11/glucagon co-agonist)
NASH2
MEDI3506(IL338 mAb)
multiple indications
roxadustatanaemia in CKD
PT027asthma
MEDI7219(GLP-1, oral)
T2D
AZD0449(inhaled JAK9 inhibitor)
asthma
nirsevimabrespiratory syncytial virus
tezepelumabsevere asthma
AZD5718(FLAP3 inhibitor)
CAD4
AZD8154(inhaled PI3Kgδ10 inhibitor)
asthma
brazikumab13
inflammatory bowel diseaseanifrolumab
lupus
AZD8601(VEGF-A mRNA5)
HF
AZD1402(IL4R11 antagonist)
asthmaPhase III lifecycle management, major
AZD2693(PNPLA36 inhibitor)
NASH
AZD7594 (velsecorat)(inhaled/nebulised SGRM12)
asthma, COPD
Fasenramultiple indications
AZD2373(APOL17)
CKD
Farxigamultiple indications
Breztriasthma
New CVRM Respiratory & Immunology 1. Glucagon-like peptide-1 2. Non-alcoholic steatohepatitis 3. 5-Lipoxygenase-activating protein 4. Coronary artery disease 5. Vascular endothelial growth factor A-modified messenger RNA 6. Patatin-like phospholipasedomain-containing protein 3 7. Apolipoprotein L1 8. Interleukin-33 9. Janus kinase 10. Phosphoinositide 3-kinase gamma/delta 11. Interleukin-4 receptor 12. Selective glucocorticoid receptor modulator 13. Subject to the aforementioned regulatory approval.
9
Full pipeline of new medicines (NMEs), 1
Status as of 29 April 2020.
Phase I Phase II Phase III20 new molecular entities 25 new molecular entities 7 new molecular entities
Under review0 new molecular entities
adavosertib#Wee1 ovarian cancer, solid tumours
AZD0466BCL2/xL haematological and solid tumours
AZD1390glioblastoma
AZD2811Aurora solid tumours, haematological malignancies
AZD4573CDK9 haematological malignancies
AZD4635A2aR inhibitor prostate cancer
AZD5153BRD4 haematological and solid tumours
AZD5991MCL1 haematological malignancies
AZD7648#DNAPK solid and haematological tumours
AZD9496SERD ER+ breast
AZD9833SERD ER+ breast
Calquence+ceralasertibBTK+ATR haematological tumours
Calquence+danvatirsenBTK+STAT3 haematological malignancies
capivasertib#AKT breast
capivasertib#AKT prostate
capivasertib+chemotherapy CAPItello-290AKT+chemotherapy mTNBC 1L
Imfinzi# (platform) COASTPD-L1+multiple novel ONC therapies NSCLC
Imfinzi# (platform) NeoCOASTPD-L1++multiple novel ONC therapies NSCLC
Imfinzi#+/-tremelimumab+chemo POSEIDONPD-L1+/-CTLA-4+SoC 1L NSCLC
Imfinzi#+/-tremelimumab+CRT ADRIATICPD-L1+/-CTLA-4+CRT LS-SCLC
Imfinzi#+adavosertib#PD-L1+Wee1 solid tumours
Imfinzi#+AZD4635PD-L1+A2aR prostate cancer
Imfinzi#+AZD5069 or Imfinzi#+ danvatirsen# PD-L1+(CXCR2 or STAT3) HNSCC bladder NSCLC
Imfinzi#+Lynparza# ORIONPD-L1+PARP 1L mNSCLC
Imfinzi#+MEDI0457#PD-L1+DNA HPV vaccine HNSCC
Imfinzi#+monalizumab#PD-L1+NKG2a solid tumours
Imfinzi#+tremelimumab HIMALAYAPD-L1+CTLA-4 1L HCC
Imfinzi#+tremelimumab KESTRELPD-L1+CTLA-4 1L HNSCC
Imfinzi#+tremelimumab+SoC NILEPD-L1+CTLA-4+SoC 1L urothelial cancer
Lynparza#+Imfinzi#+bevacizumab DUO-OPARP+PD-L1+VEGF 1L ovarian
Imfinzi#+RT (platform) CLOVERPD-L1+RT HNSCC NSCLC SCLC
Imfinzi#+tremelimumabPD-L1+CTLA-4 solid tumours
Imfinzi#+tremelimumab+chemoPD-L1+CTLA-4 1L PDAC oesophageal SCLC
Imfinzi+Koselugo (selumetinib)#PD-L1+MEK solid tumours
IPH5201#CD39 solid tumours
MEDI1191IL12 mRNA solid tumours
MEDI2228BCMA ADC multiple myeloma
MEDI5083CD40 ligand fusion protein solid tumours
MEDI5395rNDV GMCSF solid tumours
oleclumab+TagrissoCD73+EGFR EGFRm NSCLC
Imfinzi#+oleclumabPD-L1+CD73 solid tumours
Imfinzi#+tremelimumabPD-L1+CTLA-4 gastric cancer
Imfinzi#+tremelimumabPD-L1+CTLA-4 biliary tract oesophageal
Imfinzi+Lynparza# BAYOUPD-L1+PARP bladder
Lynparza#+adavosertib#PARP+Wee1 solid tumours
Lynparza#+AZD6738 VIOLETTEPARP+ATR breast
Lynparza#+Imfinzi MEDIOLAPARP+PD-L1 ovarian breast gastric SCLC
MEDI5752PD-1/CTLA-4 solid tumours
oleclumab+AZD4635CD73+A2aR prostate cancer
oleclumab+chemo or Imfinzi#+ oleclumab+chemo CD73+chemo or PD-L1+CD73+chemo pancreatic
Tagrisso combo# TATTONEGFR+PD-L1/MEK/MET NSCLC
Tagrisso+savolitinib# SAVANNAHEGFR+MET advanced EGFRm NSCLC
1 Includes novel combinations and additional indications for assets where the lead is not yet launched
# Partnered and/or in collaboration; ¶ Registrational Phase II/III trial
Oncology Precision medicine approach being explored
10
Full pipeline of new medicines (NMEs), 2
Status as of 29 April 2020.
1 Includes novel combinations and additional indications for assets where the lead is not yet launched# Partnered and/or in collaboration; ¶ Registrational Phase II/III trial
BioPharmaceuticals Precision medicine approach being explored
Phase I Phase II Phase III17 new molecular entities 20 new molecular entities 4 new molecular entities
Under review0 new molecular entities
abediterol#LABA asthma / COPD
anifrolumab# Type I IFN receptor SLE SC
anifrolumab# Type I IFN receptor lupus nephritis
anifrolumab# TULIPType I IFN receptor SLE
AZD0284RORg psoriasis / respiratory
AZD0449Inhaled JAK inhibitor asthma
AZD1402#inhaled IL-4Ra asthma
AZD2373Podocyte health nephropathy
AZD2693nonalcoholic steatohepatitis
AZD4041#orexin 1 receptor antagonist opioid use disorder
AZD4831MPO HFpEF
AZD5634inhaled ENaC cystic fibrosis
AZD5718FLAP coronary artery disease
AZD6615hypercholesterolemia CV disease
velsecorat (AZD7594)Inhaled SGRM asthma / COPD
AZD7986#DPP1 COPD
AZD8154Inhaled PI3Kgd asthma
AZD8601#VEGF-A cardiovascular
navafenterol (AZD8871)#MABA COPD
AZD9567SGRM RA / respiratory
nirsevimab#RSV mAb-YTE passive RSV immunisation
PT027ICS/SABA asthma
tezepelumab# NAVIGATOR SOURCETSLP severe uncontrolled asthma
AZD8233hypercholesterolemia cardiovascular
AZD9977MCR cardiovascular
MEDI0618#PAR2 antagonist mAb OA pain
MEDI1341#alpha synuclein parkinson's disease
MEDI1814#amyloidβ alzheimer's disease
MEDI5117# ChinaIL6 YTE rheumatoid arthritis
MEDI6570LOX-1 CV disease
MEDI7219anti-diabetic type-2 diabetes
cotadutideGLP-1/glucagon type-2 diabetes / obesity / NASH
MEDI3506Diabetic kidney disease
MEDI3506IL33 AD / COPD
MEDI5884#cholesterol modulation cardiovascular
MEDI6012LCAT cardiovascular
MEDI7352NGF/TNF OA pain / painful diabetic neuropathy
suvratoxumabα-Toxin Staphylococcus pneumonia
tezepelumab#TSLP atopic dermatitis
tezepelumab#TSLP COPD
verinuradURAT-1 chronic kidney disease
Busy news flow continues; underpinning consistent revenue growth
11
Late-stage pipeline events in the 2020-2021 timeframe
Q2 2020 H2 2020 2021Regulatorydecision
Lynparza- OC (1L) (PAOLA-1) (US)- breast cancer (BRCAm) (CN)- prostate cancer (2L) (US)
Forxiga/Farxiga- T2D CVOT (CN)- HF CVOT (US)Bevespi - COPD (CN)
Imfinzi - ES-SCLC (EU, JP)Lynparza- OC (1L) (PAOLA-1) (EU)- pancreatic cancer (1L, BRCAm) (EU)- prostate cancer (2L) (EU)Calquence - CLL (EU)
Forxiga - HF CVOT (EU, JP, CN)Brilinta/Brilique - CAD/T2D CVOT (US, EU)roxadustat - anaemia in CKD (US)Symbicort - mild asthma (CN)PT010 - COPD (US, EU)
Lynparza - prostate cancer (2L) (JP)Calquence - CLL (JP)Koselugo - NF1 (EU)
Regulatorysubmissionand/oracceptance
Imfinzi - ES-SCLC (CN)Enhertu - gastric cancer (HER2+)
Symbicort - mild asthma (EU)
Tagrisso - adjuvant NSCLC (EGFRm)Lynparza - OC (3L, BRCAm) (US)Enhertu - breast cancer (3L, HER2+) (EU)
Farxiga - CKDanifrolumab - lupus (SLE1)
Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2); adjuvant NSCLC; liver cancer (locoregional)Imfinzi +/- treme - liver cancer (1L); NSCLC (1L) (POSEIDON);head & neck cancer (1L)Lynparza - adjuvant breast cancer; prostate cancer (1L, castration-resistant)Enhertu - breast cancer (2L, HER2+)
Fasenra - nasal polyposisPT027 - asthmatezepelumab - severe asthma
Key Phase IIIdata readouts
- Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2)Imfinzi +/- treme - liver cancer (1L)
Fasenra - nasal polyposisPT027 - asthmatezepelumab - severe asthma
Imfinzi - adjuvant NSCLC; liver cancer (locoregional)Imfinzi +/- treme - NSCLC (1L) (POSEIDON) (OS); head & neck cancer (1L)Lynparza - adjuvant breast cancer; prostate cancer (1L, castration-resistant)Enhertu - breast cancer (3L, HER2+) (Phase III);breast cancer (2L, HER2+); breast cancer (HER2 low)
roxadustat - anaemia in myelodysplastic syndrome
Status as of 29 April 2020. 1. Systemic lupus erythematosus.
12
Q1 2020: 17% revenue growth; new medicines driving growth
New medicinesdrove growth
Strong revenuegrowth continued $m
Q1 2020:
+$1.0bnincremental revenue of the new
medicines compared to Q1 20191
Changes at CER.
Oncology New CVRM Respiratory & ImmunologyAbsolute values at CER. 1. Total revenue for Tagrisso, Imfinzi, Calquence, Enhertu, Farxiga, Brilinta, Lokelma, roxadustat,Fasenra, Bevespi and Breztri and product sales for Lynparza; Bevespi not shown.
14%
11%
18%
22%
5%
17%
Tota
l rev
enue
gro
wth
, per
cen
t
0
100
200
300
400
Oncology now 40% of sales and annualising as a $10bn business
13
Q1 2020: solid growth in all therapy areas and EMs
Q1 2020$m
change%
ratio%
Product sales 6,311 17 100
Oncology 2,502 34 40
New CVRM 1,098 8 17
Respiratory & Immunology 1,551 22 25
Other medicines 1,159 (6) 18
Emerging markets 2,271 16 36
- EMs ex China 857 16 14
- China 1,413 17 22
Product sales at actual exchange rates; changes at CER. 1. Emerging markets.
R&D productivity & focus drive decisions
14
Strategic value-creation framework
R&D productivity
Focus on three main therapy
areas‘Following the science’leads to innovationin and outside areas offocus
OncologyCVRM - Cardiovascular,Renal & MetabolismRespiratory & Immunology
Collaboration1
(milestones/royalty)Accelerate/enhance value; or new
medicines outside focus
Product Sales(Including Growth Platforms)
Other Operating Income2
Disposal, typically of legacy medicines outside focus
1. Medicines in which AstraZeneca maintains a significant future interest. Revenue through (recurring) milestones and royalty.2. One-off disposal income and legacy royalty income.
15
Emerging markets
Product sales performing strongly
16
Emerging markets: portfolio of diverse markets
Product sales at actual exchange rates and for FY 2019; changes at CER.
$2,211m
+52%
Respiratory& Immunology
New CVRMOncology
$1,175m+10%
Other
$1,986m
+27%
$1,133m
+41%
$2,834m
+4%Asia Pacific
$4,480m+35%
China
$246m+40%
Russia
$1,049m8%
Middle East & Africa
$8,164m+24%
Emerging markets total
$368m+7%
Brazil
$446m+16%
Other Latin America
Proportion of sales
17
Emerging markets: speciality care large opportunity
Specialty care Primary careProduct sales at actual exchange rates and for FY 2019. Speciality care includes Oncology, Brilinta, Lokelma and Fasenra.
60%
40%
56%
44%
67%
33%
47%
53%
USEurope
EMs
Est. RoW
Fast-growing and well-diversified portfolio
18
Emerging markets: top-10 medicines
Product sales at actual exchange rates and for FY 2019; changes at CER.
New medicines Sales 2019 ($m) % change % of total
Tagrisso 762 130 9
Forxiga 471 48 6
Brilique 462 49 6
Older medicines Sales 2019 ($m) % change % of total
Pulmicort 1.190 24 15
Crestor 806 - 10
Nexium 748 14 9
Seloken 686 13 8
Symbicort 547 17 7
Zoladex 492 28 6
Iressa 286 4 4
19
Emerging markets
20
Core profit & loss
Q1 2020$m
change%
% total revenue
Total revenue 6,354 17 100
- product sales 6,311 17 99
- collaboration revenue 43 70 1
Gross margin 78.1% (2.1) pp
Operating expenses1 3,600 8 57
- R&D expenses 1,336 9 21
- SG&A expenses 2,177 7 34
Other operating income 479 (19) 8
Operating profit 1,854 16 29
Tax rate 20%
EPS $1.05 21
Absolute values at actual exchange rates; changes at CER. Gross margin reflects gross profit derived from product sales, divided by product sales. 1. Includes distribution expenses.
Moody’s: A3 Stable outlook / P2 | Standard & Poor’s: BBB+ Stable outlook / A2
21
Debt maturity profile and credit ratings
Notional bond values. FX converted at 30 June 2019 spot rates (USD/EUR 0.89044; USD/GBP 0.78914). Current portion of leases of $206m are included in 2019, whilst non-current leases of $514m have been excluded from the chart.
0
500
1,000
1,500
2,000
2,500
3,000
2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2031 2037 2042 2045 2048
$m
USD EUR GBP Commercial Paper Overdraft, leases, bank collateral
22
Sustainability matters now more than ever
Some companies fall into the trap of saying ‘we are sustainable’ without asking themselves, what does that really mean? For me, sustainability means being a positive and constructive part of the societies in which we are working. And in a world, that’s changing fast – it matters more than ever.Leif JohanssonChairman of the Board, AstraZeneca
23
Commitment tosustainability
AstraZeneca use its capabilities to make the most meaningful impact where society needs it— health.
The Company believes that there is a strong connection between the health of its business, people and the planet, and each of these impact one another.
AstraZeneca’s commitment to sustainability supports the wider company purpose: Together, we push the boundaries of science to deliver life-changing medicines.
Healthyplanet
Healthypeople
Healthybusiness
+
24
AstraZeneca has well-defined sustainability priorities
Access to Healthcare
Health is at the heartof our business
Environmental Protection
The health of the planetimpacts all life
Ethics and Transparency
Healthy societies promoteequality and prosperity for all
Our ambitionsfor 2025
Address the global burden of NCDs through a holistic approach – from prevention to pipeline to treatment
Manage our environmental impact across all our activities and our products
Create positive societal impact and promote ethical behaviour in all markets across our value chain
Our focus areas
Our UnitedNations SDG
impact
• Investments in health systems• Affordability• Responsible R&D• Environment’s impact on health• Disease prevention and treatment
• Product environmental stewardship• Greenhouse gas reduction• Pharmaceuticals in the environment• Water stewardship• Waste management
• Ethical business culture• Inclusion and diversity• Talent and workforce evolution• Workforce wellbeing and Safety• Responsible supply chain• Human rights
25
Strategy forAccess to Healthcare
We remove barriers to access for people, regardless of social or economic condition
We understand the needs of people and communities living in emerging economies
We develop medicines, create supporting programmes and channel our investments
26
Impact in 2018
12+millionpeople reached
through Healthy Heart Africa, Phakamisa and
Healthy Lung
9.3millionreached through
Patient Assistance Programmes*
3+millionyouth reached through
our Young Health Programme
35,000+healthcare workers
trained*
54 countrieshave active company
initiatives
$686+million
of medicines donated by Patient Assistance
Programmes
27
Strategy forEnvironmental Protection
Our scope 1 and 2 greenhouse gas emissions targets are consistent with reductions required to keep warming to 1.5°C, and our scope 3 target is in line with current best practice.
By investing in new product design,clean technologies and more efficient processes, we save money and resources
We aim to minimise the impact of our products on the environment across the whole of their lifecycle in the face of dwindling natural resources, a growing global population, and climate-related weather events
28
Impact in 2018
$19minvested in environmental
efficiency projects in 2018
61%of our total electricity use
is sourced or generated from renewable
sources
100%of API discharges from
AstraZeneca sitesassessed as safe
>$71mTotal investment in
environmental efficiency projects since 2015
= 7%of our vehicle fleet
in Europe, North America and Japan is hybrid,plug-in or electric,
up from <1% in 2017
We foster an environment that embraces one of our core Values: ‘doing the right thing’
We empower our people to make decisions and speak up if they encounter wrongdoing
In 2017 we launched a Code of Ethics to strengthen understanding of expected behaviours and Global Policies
29
Strategy forEthics and Transparency
30
Impact in 2018
82%of supplier spend was assessed through our
third-party risk management
process
83%of employees feel AstraZeneca is a
great place to work
44.6%of women in Career
Level F roles or higher (senior middle
management)
76%of employees feel that AstraZeneca has a Speak Up
culture
31
Building an exciting company with a vibrant culture
Performing as an
enterprise team
Building a culture
of lifelong learning and development
Champions of inclusion
and diversity
32
Survey results show AstraZeneca has made strong progress
of employees agree AstraZeneca is a Great
Place to Work
84%
of employees agree that their manager
supports diversity and inclusion in the
workplace
86%
of employees have improved their existing skills, or learned new
skills, or had a development
opportunity in the last 12 months
85%
33
Great place to work
Headquarters
Gothenburg, Sweden Gaithersburg, USCambridge, UK
Strategic R&D Centre Strategic R&D Centre
34
AstraZeneca
1. In Q1 2020, speciality-care medicines comprised 49% of total revenue 2. Cardiovascular, Renal and Metabolism.
Improving financials
Nine blockbuster medicines
Returned to sustainablerevenue and earnings growth
Focus on operatingleverage and cash flow
Strong pipeline
17 Phase III medicines and significant lifecycle projects
Advancing early andmid-stage pipeline
Global presence
Balanced specialty1 andprimary-care franchises
Leading emerging marketspresence with R&D base
Innovative medicines in Oncology - CVRM2 - Respiratory & ImmunologyExperienced and proven team
Investor Relations
astrazeneca.com/investors35
Christer [email protected]: +44 20 3749 5711 M: +44 7827 836825
Josie [email protected]: +44 20 3749 5631M: +44 7880 400682
Tom [email protected]: +44 7867 975920M: +44 7867 975920
Thomas Kudsk [email protected]: +44 20 3749 5712M: +44 7818 524185
Nick [email protected]: +44 20 3749 5716 M: +44 7717 618834
Craig [email protected]: +44 20 3749 5714M: +44 7881 615764
Henry [email protected]: +44 20 3749 5797M: +44 7788 354619
Jen [email protected]: +44 20 3749 5824M: +44 7469 408333
Rosie [email protected]: +44 20 3749 5509M: +44 7384 806614
Use of AstraZeneca webcast, conference call and presentation slidesThe AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. Youmay not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZenecaMaterials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any othermaterial. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection betweenyou (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in anyway that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 FrancisCrick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com